These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38185870)

  • 41. Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Kwan B; Fuhrer T; Zhang J; Darshi M; Van Espen B; Montemayor D; de Boer IH; Dobre M; Hsu CY; Kelly TN; Raj DS; Rao PS; Saraf SL; Scialla J; Waikar SS; Sharma K; Natarajan L;
    Am J Kidney Dis; 2020 Oct; 76(4):511-520. PubMed ID: 32387023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
    Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M
    Circulation; 2024 Feb; 149(6):450-462. PubMed ID: 37952217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients.
    Żyłka A; Dumnicka P; Kuśnierz-Cabala B; Gala-Błądzińska A; Ceranowicz P; Kucharz J; Ząbek-Adamska A; Maziarz B; Drożdż R; Kuźniewski M
    Mediators Inflamm; 2018; 2018():7659243. PubMed ID: 30158836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A qualitative study documenting unmet needs in the management of diabetic kidney disease (DKD) in the primary care setting.
    Datar M; Ramakrishnan S; Montgomery E; Coca SG; Vassalotti JA; Goss T
    BMC Public Health; 2021 May; 21(1):930. PubMed ID: 34001084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.
    Otoda T; Sekine A; Uemoto R; Tsuji S; Hara T; Tamaki M; Yuasa T; Tamaki T; Matsuhisa M; Aihara KI
    Diabetes Ther; 2024 Jan; 15(1):127-143. PubMed ID: 37883001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
    Hanrahan JP; de Boer IH; Bakris GL; Wilson PJ; Wakefield JD; Seferovic JP; Chickering JG; Chien YT; Carlson K; Cressman MD; Currie MG; Milne GT; Profy AT
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):59-69. PubMed ID: 33328269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
    Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
    Diabetologia; 2021 Jun; 64(6):1256-1267. PubMed ID: 33665685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Add-on Rehmannia-6-Based Chinese Medicine in Type 2 Diabetes and CKD: A Multicenter Randomized Controlled Trial.
    Chan KW; Kwong ASK; Tan KCB; Lui SL; Chan GCW; Ip TP; Yiu WH; Cowling BJ; Taam Wong V; Lao L; Feng Y; Lai KN; Tang SCW
    Clin J Am Soc Nephrol; 2023 Sep; 18(9):1163-1174. PubMed ID: 37307005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of the longitudinal trajectory of urinary albumin/creatinine ratio in diabetic patients with adverse cardiac event risk: a retrospective cohort study.
    Li H; Ren Y; Duan Y; Li P; Bian Y
    Front Endocrinol (Lausanne); 2024; 15():1355149. PubMed ID: 38745945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum stromal cell-derived factor-1 levels are associated with diabetic kidney disease in type 2 diabetic patients.
    Lu CF; Ma JH; Su JB; Wang XQ; Liu WS; Ge XQ
    Endocr J; 2021 Sep; 68(9):1101-1107. PubMed ID: 33896872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
    Kao YW; Yen KC; Chen SW; Chao TF; Chan YH
    Diabetes Obes Metab; 2024 Sep; 26(9):3868-3879. PubMed ID: 38951860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association between neutrophil-to-lymphocyte ratio and diabetic kidney disease in type 2 diabetes mellitus patients: a cross-sectional study.
    Li X; Wang L; Liu M; Zhou H; Xu H
    Front Endocrinol (Lausanne); 2023; 14():1285509. PubMed ID: 38239986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Annual deterioration of renal function in hypertensive patients with and without diabetes.
    Polonia J; Azevedo A; Monte M; Silva JA; Bertoquini S
    Vasc Health Risk Manag; 2017; 13():231-237. PubMed ID: 28721063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Population-Based Analysis of Quality Indicators in CKD.
    Manns L; Scott-Douglas N; Tonelli M; Weaver R; Tam-Tham H; Chong C; Hemmelgarn B
    Clin J Am Soc Nephrol; 2017 May; 12(5):727-733. PubMed ID: 28377473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes.
    Kaze AD; Jaar BG; Fonarow GC; Echouffo-Tcheugui JB
    BMC Med; 2022 Mar; 20(1):127. PubMed ID: 35346165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A study of the natural history of diabetic kidney disease (DKD).
    Altemtam N; Russell J; El Nahas M
    Nephrol Dial Transplant; 2012 May; 27(5):1847-54. PubMed ID: 22058177
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.